ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20240109882A1
SERIAL NO

18231628

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
GENZYME CORPMASSACHUSETTS MASSACHUSETTS

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
DEFOSSA, Elisabeth Frankfurt am Main, DE 64 519
HEINELT, Uwe Frankfurt am Main, DE 54 495
MATTER, Hans Frankfurt am Main, DE 68 548
MENDEZ-PEREZ, Maria Frankfurt am Main, DE 18 105
RACKELMANN, Nils Frankfurt am Main, DE 14 8
RITTER, Kurt Frankfurt am Main, DE 59 1606
SZILLAT, Hauke Frankfurt am Main, DE 7 19
ZECH, Gernot Frankfurt am Main, DE 8 19

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation